GH Research (GHRS) Free Cash Flow (2020 - 2026)
GH Research (GHRS) posted quarterly Free Cash Flow of -$12.3 million for Q4 2025, down 18.14% year-over-year from -$15.0 million in Q4 2024, and up 9.76% quarter-over-quarter from -$13.6 million in Q3 2025.
Analysis
GH Research (GHRS) Free Cash Flow (2020 - 2026) Analysis & Trends
GH Research's Free Cash Flow history runs 6 years deep, the most recent figure standing at -$12.3 million for Q4 2025.
- In Q4 2025, Free Cash Flow fell 18.14% year-over-year to -$12.3 million; the TTM figure through Dec 2025 stood at -$43.4 million (down 2.83% YoY), while the FY2025 annual figure was -$43.4 million, down 2.83% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$12.3 million, up from -$13.6 million in the prior quarter.
- The five-year high for Free Cash Flow was -$1.1 million in Q1 2021, with the low at -$13.6 million in Q3 2025.
- The 5-year median for Free Cash Flow is -$8.7 million (2025), against an average of -$8.2 million.
- The sharpest annual moves came in 2021 and 2024: Free Cash Flow slumped 11800.0% in 2021, then increased 12.4% in 2024.
- GH Research's Free Cash Flow stood at -$3.9 million in 2021, then sank by 89.03% to -$7.5 million in 2022, then tumbled by 59.44% to -$11.9 million in 2023, then grew by 12.4% to -$10.4 million in 2024, then declined by 18.14% to -$12.3 million in 2025.
- Business Quant data shows GHRS's Free Cash Flow at -$12.3 million in Q4 2025, -$13.6 million in Q3 2025, and -$8.9 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | GH Research | 1.72 Bn | 1.36 Bn | - | -15.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.01 Mn |
| Mar 31, 2026 | -10.61 Mn |
| Dec 31, 2025 | -12.31 Mn |
| Sep 30, 2025 | -13.64 Mn |
| Jun 30, 2025 | -8.91 Mn |
| Mar 31, 2025 | -8.57 Mn |
| Dec 31, 2024 | -10.42 Mn |
| Sep 30, 2024 | -12.30 Mn |
| Jun 30, 2024 | -9.93 Mn |
| Mar 31, 2024 | -9.58 Mn |
| Dec 31, 2023 | -8.06 Mn |
| Sep 30, 2023 | -10.33 Mn |
| Jun 30, 2023 | -7.98 Mn |
| Mar 31, 2023 | -6.86 Mn |
| Dec 31, 2022 | -6.98 Mn |
| Sep 30, 2022 | -8.03 Mn |
| Jun 30, 2022 | -5.26 Mn |
| Mar 31, 2022 | -5.99 Mn |
| Dec 31, 2021 | -3.74 Mn |
| Sep 30, 2021 | -9.16 Mn |